Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Year of the authorized generic

Executive Summary

Deficit Reduction Act (S 1932), which was signed into law Feb. 8, delays inclusion of "authorized generics" in "best price" calculations until Jan. 1, 2007. Both the House and Senate budget reconciliation bills originally set Jan. 1, 2006 as the date for the provision to take effect. The new "best price" formula could effectively end the practice of "authorized generics" (1"The Pink Sheet" Jan. 2, 2006, p. 25). Generic Pharmaceutical Association lauds the new formula, claiming that it would yield more than $150 mil. in savings over five years...

You may also be interested in...



Medicaid Reform Bill Is A Draw For Pharma; Pharmacy Continues Its Fight

The conference report on budget reconciliation creates a new definition of the Medicaid federal upper limit for pharmacy reimbursement for multiple source drugs

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel